Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome | Zendy

Ben Djebara Mouna | Zendy; Worbe Yulia | Zendy; Schüpbach Michael | Zendy; Hartmann Andreas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome

Author(s) -

Ben Djebara Mouna,

Worbe Yulia,

Schüpbach Michael,

Hartmann Andreas

Publication year - 2007

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.21859

Subject(s) - aripiprazole , tourette syndrome , psychology , psychotherapist , psychiatry , refractory (planetary science) , tourette's syndrome , psychoanalysis , schizophrenia (object oriented programming) , physics , astrobiology

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28‐year‐old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research